Atomoxetine (Strattera )
[Back] Toxic Psychiatry   Articles (drug list)

See: Eli Lilly  ADHD drugs  Amphetamines

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. It is manufactured and marketed under the brand name Strattera® by Eli Lilly and Company.

[Media May 2006] Eli Lilly's Strattera - 130 reports of suicidality in one month Strattera is a failed antidepressant, which Eli Lilly didn't succeed to get approved. It was recycled and used as an "ADHD medication", and marketed as the first "non stimulant medication for ADHD". As many parents, despite all published lies about the "benefits" of stimulants like Ritalin, Concerta and Adderall, don't want to give dangerous narcotic drugs to their kids, Lilly saw the chance to get a good market share for Strattera.

[Media March 2006] MHRA forbids Sweden to reveal Strattera suicide data The British Medicines and Healthcare products Regulatory Agency (MHRA) has forbidden Swedish authorities to reveal Strattera suicide data. A release in Sweden of data about suicides and suicide attempts from Eli Lilly's Strattera is said to hurt the relations between the two countries.

[Media April 2006] Eli Lilly withheld disastrous effects of Strattera from parents and children

External links
Children's Deaths Caused from ADD & ADHD Drugs 12-Year-Old Adrian David Wade was born on November 09, 1991. 115 days after taking Strattera, with no signs he committed suicide on October 23, 2004

[Nov 2006] Eli Lilly's Strattera - 130 reports of suicidality in one month

[Aug 2006] Strattera - 10,988 adverse "psychiatric reactions" reported in less than three years

[Jan 2006] Eli Lilly's and Christopher Gillberg's failed experiment with Strattera